Amryt Pharma

39 results

The drug Oleogel-S10 – also referred to as Filsuvez – is a gel which is a first therapy for patients with epidermolysis bullosa (EB). Photograph: iStock

Irish biotech company Amryt Pharma has been granted a priority review of a new drug application for its treatment for a rare medical condition known a(...)

Amryt has asked for a  priority review, which can expedite the review process. Photograph: iStock

Irish biotech company Amryt Pharma has completed the rolling submission to US authorities of a New Drug Application (NDA) for a rare medical condition(...)

Joe Wiley, chief executive of Amryt Pharma, which has raised €33 million in a share placing

Amryt Pharma, an Irish biotech company developing a drug for a rare medical condition known as “butterfly skin” has raised $40 million (€33 million) i(...)

In September, Amryt announced positive data from trials of a new drug for the rare skin condition epidermolysis bullosa (EB)

Dublin-based biopharmaceutical company Amryt Pharma said revenue rose 19 per cent to $49.3 million (€41.7 million) in the third quarter of 2020. The(...)

Swixx BioPharma is one of the largest agents for ethical pharmaceuticals serving research-based biopharma across central and eastern Europe. Photograph: Kiyoshi Ota/Bloomberg

Dublin pharma company Amryt said on Monday it has appointed Swiss pharma agent Swixx BioPharma to distribute its cholesterol drug Lojuxta across centr(...)

Blistering caused by epidermolysis bullosa (EB). Irish company Amryt  has developing a drug for the rare medical condition. Photograph: Dave Meehan

Shares in an Irish company developing a drug for a rare medical condition known as “butterfly skin” jumped over 50 per cent on Wednesday morning on th(...)

Mackin Group founder Andrew Mackin: “Spend time on personal development that will instil good habits.”

The first four of eight nominees in the International category of the EY Entrepreneur of the Year competition are profiled this week. The awards are r(...)

Amryt Pharma focuses on developing treatments to help patients with rare and orphan diseases. Photograph: iStock

Dublin-listed biopharmaceutical company Amryt Pharma has announced that an institutional investor has exercised subscription rights relating to four m(...)

Amryt Pharma, which focuses on developing treatments to help patients with rare and orphan diseases, expects its listing on New York’s Nasdaq to complete in July. Photograph: iStock

Amryt Pharma, the Dublin-based biopharmaceutical company, almost doubled the total remuneration of its boss last year to $1.6 million (€1.42 million) (...)

File photo

Amryt Pharma, which makes treatments for rare conditions, has filed a registration statement for its impending US listing on the Nasdaq. The company,(...)

  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »